Japan Cancer Vaccines Market Size- By Vaccine Type, By Indication, By Patient Type- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Japan Cancer Vaccines Market Overview

According to SPER Market Research, the Japan Cancer Vaccines Market is estimated to reach USD 4.68 billion by 2033 with a CAGR 18.04%.

The cancer vaccine market is a part of the healthcare industry that focuses on developing vaccines to prevent or treat cancer. Cancer is a disease in which cells in the body grow uncontrollably and can spread to other parts of the body. Cancer vaccines aim to activate the immune system to target and eliminate cancer cells. These vaccines work by either preventing cancer from developing or by treating an existing cancer by slowing its growth or killing cancer cells.

What challenges does the Japan Cancer Vaccines Market face?

Despite the opportunities for growth, the Japan cancer vaccines market also faces several challenges. One of the major challenges is the high cost of developing and producing cancer vaccines. The process of developing and testing vaccines can be expensive and time-consuming, which can make it difficult for smaller companies to compete in the market. Another challenge is the regulatory landscape in Japan, which can be complex and difficult to navigate.

Scope of the Report

Report Metric Details:

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Vaccine Type, By Indication, By Patient Type

Regions covered Tokyo, Kyoto, Osaka, Yokohama, Kobe, Others

Companies Covered Aduro BioTech Inc., Astellas Pharma Inc., Bristol-Myers Squibb, CYTLIMIC, Oncolys BioPharma Inc., Takara Bio, Takeda Pharmaceutical, tella Inc.

Japan Cancer Vaccines Market Segmentation:

By Vaccine Type: Based on the Vaccine Type, Japan Cancer Vaccines Market is segmented as; Prevention Vaccines, Treatment Vaccines, Oncolytic Viruses.

By Indication: Based on the Indication, Japan Cancer Vaccines Market is segmented as; Prostate Cancer, Cervical Cancer, Other.

By Patient Type: Based on the Patient Type, Japan Cancer Vaccines Market is segmented as; Paediatric, Adult.

By Region: This report also provides the data for key regional segments of Tokyo, Kyoto, Osaka, Yokohama, Kobe, Others.

Product Code: HLCA2333

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan Cancer Vaccines Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Japan Cancer Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cancer Vaccines Market

7. Japan Cancer Vaccines Market, By Vaccine Type (USD Million)

7.1. Japan Cancer Vaccines Market Value Share and Forecast, By Vaccine Type, 2023-2033
7.2. Prevention Vaccines
- 7.2.1. HPV
- 7.2.2. HBV
7.3. Treatment Vaccines
- 7.3.1. Antigen vaccines
- 7.3.2. Dendritic cell vaccines
- 7.3.3. DNA vaccines
- 7.3.4. Whole tumor vaccines
- 7.3.5. Anti-idiotype vaccines
7.4. Oncolytic Viruses

8. Japan Cancer Vaccines Market, By Indication (USD Million)

8.1. Japan Cancer Vaccines Market Value Share and Forecast, By Indication, 2023-2033
8.2. Prostate Cancer
8.3. Cervical Cancer
8.4. Others

9. Japan Cancer Vaccines Market, By Patient Type (USD Million)

9.1. Japan Cancer Vaccines Market Value Share and Forecast, By Patient Type, 2023-2033
9.2. Paediatric
9.3. Adult

10. Japan Cancer Vaccines Market Forecast, 2019-2033 (USD Million)

10.1. Japan Cancer Vaccines Market Size and Market Share

11. Japan Cancer Vaccines Market, By Vaccine Type, 2019-2033 (USD Million)

11.1. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2019-2026)
11.2. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2027-2033)

12. Japan Cancer Vaccines Market, By Indication, 2019-2033 (USD Million)

12.1. Japan Cancer Vaccines Market Size and Market Share by Indication (2019-2026)
12.2. Japan Cancer Vaccines Market Size and Market Share by Indication (2027-2033)

13. Japan Cancer Vaccines Market, By Patient Type, 2019-2033 (USD Million)

13.1. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2019-2026)
13.2. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2027-2033)

14. Japan Cancer Vaccines Market, By Region, 2019-2033 (USD Million)

14.1. Japan Cancer Vaccines Market Size and Market Share by Region (2019-2026)
14.2. Japan Cancer Vaccines Market Size and Market Share by Region (2027-2033)
14.3. Tokyo
14.4. Kyoto
14.5. Osaka
14.6. Yokohama
14.7. Kobe
14.8. Others

15. Company Profile

15.1. Aduro BioTech Inc.
- 15.1.1. Company details
- 15.1.2. Financial outlook
- 15.1.3. Product summary
- 15.1.4. Recent developments
15.2. Astellas Pharma Inc.
- 15.2.1. Company details
- 15.2.2. Financial outlook
- 15.2.3. Product summary
- 15.2.4. Recent developments
15.3. Bristol-Myers Squibb
- 15.3.1. Company details
- 15.3.2. Financial outlook
- 15.3.3. Product summary
- 15.3.4. Recent developments
15.4. CYTLIMIC
- 15.4.1. Company details
- 15.4.2. Financial outlook
- 15.4.3. Product summary
- 15.4.4. Recent developments
15.5. Oncolys BioPharma Inc.
- 15.5.1. Company details
- 15.5.2. Financial outlook
- 15.5.3. Product summary
- 15.5.4. Recent developments
15.6. Takara Bio
- 15.6.1. Company details
- 15.6.2. Financial outlook
- 15.6.3. Product summary
- 15.6.4. Recent developments
15.7. Takeda Pharmaceutical
- 15.7.1. Company details
- 15.7.2. Financial outlook
- 15.7.3. Product summary
- 15.7.4. Recent developments
15.8. tella Inc
- 15.8.1. Company details
- 15.8.2. Financial outlook
- 15.8.3. Product summary
- 15.8.4. Recent developments